United Kingdom

Pulmatrix Inc (PULM.OQ)

PULM.OQ on NASDAQ Stock Exchange Global Market

19 Apr 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Pulmatrix posts Q3 net loss of $0.22 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Pulmatrix Inc :Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials.Q3 revenue $300,000 versus $100,000.Qtrly ‍net loss per share attributable to common stockholders $0.22​.As of September 30, 2017, Pulmatrix had $6.4 million in cash and cash equivalents, compared to $4.2 million as of December 31, 2016​.  Full Article

FDA grants orphan drug status to Pulmatrix's PUR1900
Wednesday, 17 Aug 2016 

Pulmatrix Inc : Pulmatrix receives orphan drug designation from the FDA for inhaled drug to treat pulmonary fungal infections in cystic fibrosis patients .FDA granted co's request for orphan drug status for drug for treating pulmonary fungal infections in cystic fibrosis patients, named PUR1900.  Full Article

Pulmatrix reports quarterly loss per share $0.62
Thursday, 4 Aug 2016 

Pulmatrix Inc : Quarterly loss per share $0.62 .Revenues for Q2 of 2016 were $0.3 million, compared to $0.2 million for Q2 of 2015.  Full Article

Pulmatrix and Mylan collaborate for pilot pharmacokinetic clinical study
Tuesday, 19 Jul 2016 

Pulmatrix Inc : Pulmatrix led pilot pharmacokinetic clinical study and supportive development work with collaborative support from Mylan . Financial terms of agreement are confidential . Announced positive topline data from a phase 1 pilot pharmacokinetic bioavailability trial of PUR0200 .Mylan has retained an option for PUR0200 EX-U.S. rights based on successful completion of clinical study.  Full Article

Pulmatrix Inc files for mixed shelf of upto $30 mln
Friday, 15 Jul 2016 

Pulmatrix Inc :Pulmatrix Inc files for mixed shelf of upto $30 mln - SEC filing.  Full Article

BRIEF-Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering